AKTUALITĀTES
   
48832

Arī ar HIV inficētajiem būs efektīvas zāles pret C hepatītu
Apskatīt komentārus (0)


18.10.2014


BIOTRON izpilddirektors Dr. M. Millers nosauca paveiktā darba rezultātus par bezprecedentiem un izteica cerības uz ātro BIT225 komercializāciju, piebilstot, kā šis preparāts būs ļoti efektīvs dubultinfekcijas HIV/VHC gadījumā.
***************************************************************  
Biotron managing director Dr Michelle Miller said data from the trial supported BIT225 as a potential new therapy for Hepatitis C, especially for patients with both HIV and Hepatitis C who typically had more serious Hepatitis C infection and fewer treatment options.
"Both HIV and HCV viruses present substantial challenges for treatment and represent multi-billion-dollar markets," Dr Miller said.
"We look forward to progressing commercialisation of BIT225 as a valuable new therapy that will work in combination with current and future treatment strategies."
Dr Miller said treatment including BIT225 could benefit patients in that it was more effective, required a shorter treatment time and was less expensive.
Read more at http://www.9news.com.au/national/2014/10/10/16/51/biotron-shares-soar-on-hep-c-data#LTVe8pMoJycCrCoM.99

 


 
      Atpakaļ

atstāj tukšu: atstāj tukšu:
vārds:




Ievadiet drošības kodu:

Visual CAPTCHA



Gaismas iela 19 k-8, Ķekava, Ķekavas pagasts, Ķekavas novads, LV-2123, Latvija

Logo +371 26062077
Logo apvieniba@apvienibahiv.lv